Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells

Emiliano Cocco, Yang Deng, Erik M. Shapiro, Ileana Bortolomai, Salvatore Lopez, Ken Lin, Stefania Bellone, Jiajia Cui, Gulden Menderes, Jonathan D. Black, Carlton L. Schwab, Elena Bonazzoli, Fan Yang, Federica Predolini, Luca Zammataro, Gary Altwerger, Christopher De Haydu, Mitchell Clark, Julio Alvarenga, Elena Ratner & 6 others Masoud Azodi, Dan Arin Silasi, Peter E. Schwartz, Babak Litkouhi, W. Mark Saltzman, Alessandro D. Santin

Research output: Contribution to journalArticle

  • 7 Citations

Abstract

Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and -4, the receptors for Clostridium perfringens enterotoxin (CPE), are overexpressed in more than 70% of these tumors. Here, we synthesized and characterized poly (lactic-co-glycolic-acid) (PLGA) nanoparticles (NPs) modified with the carboxy-terminal-binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. As a therapeutic payload, we generated a plasmid encoding for the diphtheria toxin subunit- A (DT-A) under the transcriptional control of the p16 promoter, a gene highly differentially expressed in ovarian cancer cells. Flow cytometry and immunofluorescence demonstrated that c-CPE-NPs encapsulating the cytomegalovirus (CMV) GFP plasmid (CMV GFP c-CPE-NP) were significantly more efficient than control NPs modified with a scrambled peptide (CMV GFP scr-NP) in transfecting primary chemotherapy- resistant ovarian tumor cell lines in vitro (P = 0.03). Importantly, c-CPE-NPs encapsulating the p16 DT-A vector (p16 DT-A c-CPE-NP) were significantly more effective than control p16 DT-A scr-NP in inducing ovarian cancer cell death in vitro (% cytotoxicity: mean ± SD = 32.9 ± 0.15 and 7.45 ± 7.93, respectively, P = 0.03). In vivo biodistribution studies demonstrated efficient transfection of tumor cells within 12 hours after intraperitoneal injection of CMV GFP c-CPE-NP in mice harboring chemotherapy-resistant ovarian cancer xenografts. Finally, multiple intraperitoneal injections of p16 DT-A c-CPE-NP resulted in a significant inhibition of tumor growth compared with control NP in chemotherapy-resistant tumorbearing mice (P = 0.041). p16 DT-A c-CPE-NP may represent a novel dual-targeting therapeutic approach for the selective delivery of gene therapy to chemotherapy-resistant ovarian cancer cells.

LanguageEnglish (US)
Pages323-333
Number of pages11
JournalMolecular Cancer Therapeutics
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2017

Profile

Ovarian Neoplasms
Nanoparticles
Suicide
Drug Therapy
Diphtheria Toxin
Genes
Cytomegalovirus
Intraperitoneal Injections
Genetic Therapy
Neoplasms
Claudin-3
Plasmids
Claudin-4
Clostridium enterotoxin
Tumor Cell Line
Heterografts
Fluorescent Antibody Technique
Transfection
Flow Cytometry
Cell Death

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells. / Cocco, Emiliano; Deng, Yang; Shapiro, Erik M.; Bortolomai, Ileana; Lopez, Salvatore; Lin, Ken; Bellone, Stefania; Cui, Jiajia; Menderes, Gulden; Black, Jonathan D.; Schwab, Carlton L.; Bonazzoli, Elena; Yang, Fan; Predolini, Federica; Zammataro, Luca; Altwerger, Gary; De Haydu, Christopher; Clark, Mitchell; Alvarenga, Julio; Ratner, Elena; Azodi, Masoud; Silasi, Dan Arin; Schwartz, Peter E.; Litkouhi, Babak; Saltzman, W. Mark; Santin, Alessandro D.

In: Molecular Cancer Therapeutics, Vol. 16, No. 2, 01.02.2017, p. 323-333.

Research output: Contribution to journalArticle

Cocco, E, Deng, Y, Shapiro, EM, Bortolomai, I, Lopez, S, Lin, K, Bellone, S, Cui, J, Menderes, G, Black, JD, Schwab, CL, Bonazzoli, E, Yang, F, Predolini, F, Zammataro, L, Altwerger, G, De Haydu, C, Clark, M, Alvarenga, J, Ratner, E, Azodi, M, Silasi, DA, Schwartz, PE, Litkouhi, B, Saltzman, WM & Santin, AD 2017, 'Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells' Molecular Cancer Therapeutics, vol 16, no. 2, pp. 323-333. DOI: 10.1158/1535-7163.MCT-16-0501
Cocco, Emiliano ; Deng, Yang ; Shapiro, Erik M. ; Bortolomai, Ileana ; Lopez, Salvatore ; Lin, Ken ; Bellone, Stefania ; Cui, Jiajia ; Menderes, Gulden ; Black, Jonathan D. ; Schwab, Carlton L. ; Bonazzoli, Elena ; Yang, Fan ; Predolini, Federica ; Zammataro, Luca ; Altwerger, Gary ; De Haydu, Christopher ; Clark, Mitchell ; Alvarenga, Julio ; Ratner, Elena ; Azodi, Masoud ; Silasi, Dan Arin ; Schwartz, Peter E. ; Litkouhi, Babak ; Saltzman, W. Mark ; Santin, Alessandro D./ Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells. In: Molecular Cancer Therapeutics. 2017 ; Vol. 16, No. 2. pp. 323-333
@article{8a54a846e3d74b01b96ef5f376b5b73a,
title = "Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells",
abstract = "Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and -4, the receptors for Clostridium perfringens enterotoxin (CPE), are overexpressed in more than 70{\%} of these tumors. Here, we synthesized and characterized poly (lactic-co-glycolic-acid) (PLGA) nanoparticles (NPs) modified with the carboxy-terminal-binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. As a therapeutic payload, we generated a plasmid encoding for the diphtheria toxin subunit- A (DT-A) under the transcriptional control of the p16 promoter, a gene highly differentially expressed in ovarian cancer cells. Flow cytometry and immunofluorescence demonstrated that c-CPE-NPs encapsulating the cytomegalovirus (CMV) GFP plasmid (CMV GFP c-CPE-NP) were significantly more efficient than control NPs modified with a scrambled peptide (CMV GFP scr-NP) in transfecting primary chemotherapy- resistant ovarian tumor cell lines in vitro (P = 0.03). Importantly, c-CPE-NPs encapsulating the p16 DT-A vector (p16 DT-A c-CPE-NP) were significantly more effective than control p16 DT-A scr-NP in inducing ovarian cancer cell death in vitro ({\%} cytotoxicity: mean ± SD = 32.9 ± 0.15 and 7.45 ± 7.93, respectively, P = 0.03). In vivo biodistribution studies demonstrated efficient transfection of tumor cells within 12 hours after intraperitoneal injection of CMV GFP c-CPE-NP in mice harboring chemotherapy-resistant ovarian cancer xenografts. Finally, multiple intraperitoneal injections of p16 DT-A c-CPE-NP resulted in a significant inhibition of tumor growth compared with control NP in chemotherapy-resistant tumorbearing mice (P = 0.041). p16 DT-A c-CPE-NP may represent a novel dual-targeting therapeutic approach for the selective delivery of gene therapy to chemotherapy-resistant ovarian cancer cells.",
author = "Emiliano Cocco and Yang Deng and Shapiro, {Erik M.} and Ileana Bortolomai and Salvatore Lopez and Ken Lin and Stefania Bellone and Jiajia Cui and Gulden Menderes and Black, {Jonathan D.} and Schwab, {Carlton L.} and Elena Bonazzoli and Fan Yang and Federica Predolini and Luca Zammataro and Gary Altwerger and {De Haydu}, Christopher and Mitchell Clark and Julio Alvarenga and Elena Ratner and Masoud Azodi and Silasi, {Dan Arin} and Schwartz, {Peter E.} and Babak Litkouhi and Saltzman, {W. Mark} and Santin, {Alessandro D.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1158/1535-7163.MCT-16-0501",
language = "English (US)",
volume = "16",
pages = "323--333",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Dual-targeting nanoparticles for in vivo delivery of suicide genes to chemotherapy-resistant ovarian cancer cells

AU - Cocco,Emiliano

AU - Deng,Yang

AU - Shapiro,Erik M.

AU - Bortolomai,Ileana

AU - Lopez,Salvatore

AU - Lin,Ken

AU - Bellone,Stefania

AU - Cui,Jiajia

AU - Menderes,Gulden

AU - Black,Jonathan D.

AU - Schwab,Carlton L.

AU - Bonazzoli,Elena

AU - Yang,Fan

AU - Predolini,Federica

AU - Zammataro,Luca

AU - Altwerger,Gary

AU - De Haydu,Christopher

AU - Clark,Mitchell

AU - Alvarenga,Julio

AU - Ratner,Elena

AU - Azodi,Masoud

AU - Silasi,Dan Arin

AU - Schwartz,Peter E.

AU - Litkouhi,Babak

AU - Saltzman,W. Mark

AU - Santin,Alessandro D.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and -4, the receptors for Clostridium perfringens enterotoxin (CPE), are overexpressed in more than 70% of these tumors. Here, we synthesized and characterized poly (lactic-co-glycolic-acid) (PLGA) nanoparticles (NPs) modified with the carboxy-terminal-binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. As a therapeutic payload, we generated a plasmid encoding for the diphtheria toxin subunit- A (DT-A) under the transcriptional control of the p16 promoter, a gene highly differentially expressed in ovarian cancer cells. Flow cytometry and immunofluorescence demonstrated that c-CPE-NPs encapsulating the cytomegalovirus (CMV) GFP plasmid (CMV GFP c-CPE-NP) were significantly more efficient than control NPs modified with a scrambled peptide (CMV GFP scr-NP) in transfecting primary chemotherapy- resistant ovarian tumor cell lines in vitro (P = 0.03). Importantly, c-CPE-NPs encapsulating the p16 DT-A vector (p16 DT-A c-CPE-NP) were significantly more effective than control p16 DT-A scr-NP in inducing ovarian cancer cell death in vitro (% cytotoxicity: mean ± SD = 32.9 ± 0.15 and 7.45 ± 7.93, respectively, P = 0.03). In vivo biodistribution studies demonstrated efficient transfection of tumor cells within 12 hours after intraperitoneal injection of CMV GFP c-CPE-NP in mice harboring chemotherapy-resistant ovarian cancer xenografts. Finally, multiple intraperitoneal injections of p16 DT-A c-CPE-NP resulted in a significant inhibition of tumor growth compared with control NP in chemotherapy-resistant tumorbearing mice (P = 0.041). p16 DT-A c-CPE-NP may represent a novel dual-targeting therapeutic approach for the selective delivery of gene therapy to chemotherapy-resistant ovarian cancer cells.

AB - Ovarian cancer is the most lethal gynecologic cancer. Claudin-3 and -4, the receptors for Clostridium perfringens enterotoxin (CPE), are overexpressed in more than 70% of these tumors. Here, we synthesized and characterized poly (lactic-co-glycolic-acid) (PLGA) nanoparticles (NPs) modified with the carboxy-terminal-binding domain of CPE (c-CPE-NP) for the delivery of suicide gene therapy to chemotherapy-resistant ovarian cancer cells. As a therapeutic payload, we generated a plasmid encoding for the diphtheria toxin subunit- A (DT-A) under the transcriptional control of the p16 promoter, a gene highly differentially expressed in ovarian cancer cells. Flow cytometry and immunofluorescence demonstrated that c-CPE-NPs encapsulating the cytomegalovirus (CMV) GFP plasmid (CMV GFP c-CPE-NP) were significantly more efficient than control NPs modified with a scrambled peptide (CMV GFP scr-NP) in transfecting primary chemotherapy- resistant ovarian tumor cell lines in vitro (P = 0.03). Importantly, c-CPE-NPs encapsulating the p16 DT-A vector (p16 DT-A c-CPE-NP) were significantly more effective than control p16 DT-A scr-NP in inducing ovarian cancer cell death in vitro (% cytotoxicity: mean ± SD = 32.9 ± 0.15 and 7.45 ± 7.93, respectively, P = 0.03). In vivo biodistribution studies demonstrated efficient transfection of tumor cells within 12 hours after intraperitoneal injection of CMV GFP c-CPE-NP in mice harboring chemotherapy-resistant ovarian cancer xenografts. Finally, multiple intraperitoneal injections of p16 DT-A c-CPE-NP resulted in a significant inhibition of tumor growth compared with control NP in chemotherapy-resistant tumorbearing mice (P = 0.041). p16 DT-A c-CPE-NP may represent a novel dual-targeting therapeutic approach for the selective delivery of gene therapy to chemotherapy-resistant ovarian cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=85011632718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011632718&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-16-0501

DO - 10.1158/1535-7163.MCT-16-0501

M3 - Article

VL - 16

SP - 323

EP - 333

JO - Molecular Cancer Therapeutics

T2 - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -